Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250548 · ClinicalTrials.gov registry record · Phase 2
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01250548 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 34 participants.
The verdict
NCT01250548, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis. The investigators will be collecting information in this study to help us determine - * the safety of apremilast in patients with active rheumatoid arthritis * how long it takes for patients with active rheumatoid arthritis to respond to apremilast * how long the effects of apremilast last after the treatment has ended.
Interventions
- OTHER Placebo
- BIOLOGICAL apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250548
The ClinicalTrials.gov registry entry for NCT01250548 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01250548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250548 about?
NCT01250548 is a clinical study titled "The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)". The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis. The investigators will be collecting information in this study to help us determine - * the safety of apremilast in...
What is the current status of trial NCT01250548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2010-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01250548?
The interventions under investigation include: Placebo (OTHER), apremilast (BIOLOGICAL).
Who is sponsoring clinical trial NCT01250548?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.